Prothena | PRTA - Cost Of Sales

Stock Price
9.07
Daily Change
-0.52 -5.42%
Monthly
-15.94%
Yearly
24.42%
Q2 Forecast
9.47

Prothena reported $28.94M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Exelixis USD 19.95M 6.53M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
MacroGenics USD 10.12M 34.18M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Xoma 116K 112.7K Jun/2024